Human Milk Oligosaccharides (HMOs): the complete guide from production to applications
Human milk oligosaccharides: structure, types, production methods, regulatory status, applications from infant formula to adult health.
HMOs for gut health, immunity and beyond: Mechanisms, benefits, and applications explained
How do human milk oligosaccharides improve gut health? Discover HMO prebiotic effects, microbiome modulation, and adult clinical evidence.
Precision fermentation for HMOs: How synthetic biology enables scalable glycan production
How precision fermentation produces HMOs at scale. Strain engineering, fermentation, downstream processing, and analytical QC.
Now authorized in Canada: inbiose’s 2′-FL
Inbiose’s GlycoActive™ 2FL can now be formulated in Canadian products
Inbiose appoints Dirk Abeel and Dominique Poiroux as strategic board advisors to power global growth
BLOG H2 title goes here Inbiose, a leader in Human Milk Oligosaccharide (HMO) production through precision fermentation, is accelerating its growth trajectory with the addition of Dirk Abeel and Dominique Poiroux as Board Advisors. Their combined expertise in scaling biotech ventures, commercial strategy, and global market expansion will supercharge Inbiose’s mission to redefine health through advanced milk bioactives. […]
Inbiose ranks #3 in Belgium for the 2024 FoodTech 500
BLOG H2 title goes here 🚀 Inbiose ranks #3 in Belgium for the 2024 FoodTech 500, placing #13 in Biotech/Synthetization and #148 globally! We believe ingredient innovation is key to a healthier future, and this recognition highlights biotech’s impact on food, health, and sustainability. But with only 2 out of 5 FoodTech 500 companies from […]
Inbiose achieves full regulatory approval in China for its human milk oligosaccharide 2’FL
BLOG H2 title goes here Ghent Belgium – 12 December, 2023 Inbiose, a leading biotech company active in the development of Human Milk Oligosaccharides (HMOs), is pleased to announce that it has received full regulatory approval for its 2’‐fucosyllactose (2’‐FL) in China by the ministries of health and agriculture. 2’‐FL is the main HMO […]
Inbiose applies for FDA GRAS approval of four new Human Milk Oligosaccharides
BLOG H2 title goes here Inbiose, a leading biotech company active in the development of Human Milk Oligosaccharides (HMOs), is pleased to announce that it has submitted its application for a Generally Recognized as Safe (GRAS) approval by the US Food & Drug Administration (FDA) of four HMOs, specifically 6’-Sialyllactose (6’SL), 3-Sialyllactose (3’SL), Lacto-N-Tetraose (LNT) […]
Inbiose receives FDA No Question letter for GRAS notices on five Human Milk Oligosaccharides
BLOG H2 title goes here Ghent Belgium – 6 December, 2023 Inbiose, a leading biotech company active in the development of Human Milk Oligosaccharides (HMOs), is pleased to announce that it has received a no question letter from the United States’ Food and Drug Administration (FDA) regarding its Generally Recognized as Safe Substances (GRAS) […]
Inbiose receives €15 million funding from EIB
BLOG H2 title goes here Inbiose signs €15 million loan with European Investment Bank to scale up its research and development and accelerate market launch of its products. EIB financing will strengthen home-grown European technology by providing Inbiose with long-term, non-dilutive financing in support of its business plans. The financing for Inbiose is being made […]